Description

Xanax 1 mg (Alprazolam) Tablets

Xanax 1 mg is an intermediate-strength oral formulation containing alprazolam, a high-potency, short- to intermediate-acting triazolobenzodiazepine. It functions by binding to specific stereospecific regulatory sites on $\text{GABA}_A$ receptor complexes in the central nervous system, enhancing the inhibitory actions of gamma-aminobutyric acid ($\text{GABA}$). This mechanism produces rapid anxiolytic, sedative, muscle-relaxing, and anti-panic effects.

Product Overview

Primary Indications

Xanax 1 mg is indicated for use under direct medical supervision for:

• Panic Disorder: Treatment of panic disorder, with or without agoraphobia, characterized by recurrent, unexpected panic attacks and anticipatory anxiety.

• Generalized Anxiety Disorder (GAD): Short-term management of acute, severe anxiety symptoms or anxiety-associated depressive states where rapid relief is clinically warranted.

• Acute Anxiety Episodes: Short-term stabilization of acute situational or chronic anxiety exacerbations unresponsive to lower doses or baseline pharmacotherapy.

Key Information & Precautions

• High Potency & Dosing: Alprazolam is extremely potent (1 mg of alprazolam is approximately equivalent to 10 mg to 20 mg of diazepam). Dose initiation is typically much lower (0.25 mg to 0.5 mg), with the 1 mg strength reserved for titrated, established maintenance dosing under clinician review.

• Risk of Abuse, Misuse, and Addiction: Because of its rapid onset and high affinity for $\text{GABA}_A$ receptors, alprazolam carries a particularly high liability for psychological dependence, physical dependence, tolerance, and drug misuse compared to many longer-acting benzodiazepines.

• Severe Withdrawal and Rebound Anxiety: Due to its short half-life, inter-dose anxiety can occur. Abrupt cessation or rapid dose reduction can precipitate severe, potentially life-threatening withdrawal phenomena, including seizures, delirium, psychosis, autonomic instability, and extreme rebound panic. Discontinuation requires a meticulous, slow taper guided by a physician.

• CNS Depression and Psychomotor Impairment: Induces marked sedation, drowsiness, ataxia, and slowed cognitive processing. Patients should not operate motor vehicles or heavy machinery while under therapy.

• Black Box Warning — Opioid / Depressant Interaction: Concomitant administration with opioids, ethanol, or other central nervous system depressants carries a high risk of profound respiratory depression, coma, and fatal overdose.

• Metabolism & Hepatic Interactions: Alprazolam is predominantly cleared via hepatic CYP3A4 enzymes. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) substantially increase alprazolam plasma concentrations and are contraindicated or require severe dose adjustments.